Sanjay Bambhaniya · May 27, 2026

Hexagon Nutrition IPO Review | APPLY or AVOID?

Mainboard Book Build Listed

FMCG

BSE, NSE

Price Band

₹42 - ₹45

Issue Size

₹138.87 Cr.

Lot Size

333

Min. Investment

₹14,985

Live GMP ₹1.25

2.78% Est. Listing: ₹46.25

SIP Calc Compare

IPO Timeline

DRHP FILED December 25, 2025

OPEN June 5, 2026

CLOSE June 9, 2026

ALLOTMENT June 10, 2026

LISTING June 12, 2026

IPO DETAILS REVIEW GMP SUBSCRIPTION ALLOTMENT STATUS

Hexagon Nutrition Ltd. started in 1993. It operates in the FMCG industry and provides micronutrient premixes and clinical foods to its customers across India and seventy-five other nations. This business is based in Mumbai. This IPO review covers the main facts of the offer. It helps you decide if the issue fits your portfolio.
Hexagon Nutrition Limited shows steady growth but the revenue concentration remains a key point to consider for investors. (The company relies heavily on its premix formulation segment for massive parts of its revenue.)

✅ Strengths

Diversified nutrition product portfolio (Offers clinical and public wellness products)
Wider international distribution reach (Exports products to 75 overseas nations)
Operates multiple specialized regional production units
EBITDA margins show solid continuous improvement
Preferred global supply partner
Maintains high market share in programs
Robust research development capabilities – Strong in-house centers drive product innovation

⚠️ Challenges

Zero fresh issue capital (Entire offer is an sale transaction)
Heavy segment revenue concentration (Premix formulation business drives half earnings)
Significant client concentration risks (Top ten customers command large revenue)
Volatile raw material pricing (Lack of long-term input supply contracts)
Changing consumer health choices (Evolving wellness preferences affect total demand)
Complex international regulatory changes (Global compliance policies impact manufacturing costs)

Financial Update

The company released its restated financial statements for the year ending March 31, 2025. Total revenue was ₹324.93 crore increased from ₹297.73 crore in previous year. The net profit for the same period was ₹24.38 crore increased from ₹12.21 crore in previous year. (The firm generates a total income of ₹275.57 crore during 9 month period ending December 31, 2025. Net profit touches ₹27.03 crore during this same period. The financial statement reflects expanding operational efficiency as net profit margins scale up to 9.81%.) This trend should be carefully studied prior to any investment.

IPO Valuation

The upper price band is ₹45. This price leads to a Price-to-Earnings (P/E) ratio of 25.71. The average P/E for the industry is 67.54. (The offer looks fully priced based on its historical performance numbers. The asking price reflects a post-issue P/E ratio of 22.73 when calculated against full Fiscal 2025 financial results. The company targets a total market capitalization of ₹553.13 crore at the highest price limit.) The initial offer price looks fully valued but remains cheaper than premium listed sector giants.

IPO Objective

The company will use the proceeds of the offer to meet stated objectives:

To carry out an offer for sale of equity shares by selling to stakeholders
To achieve the corporate benefits of listing the equity shares on the stock exchanges
To provide a successful exit route to the existing investors of the company

Promoters & Lead Manager

Arun Kelkar and Subhash Kelkar along with Vikram Kelkar look after corporate administration as main promoters.
Nikhil Kelkar and Aditya Kelkar steer the core business operations as active promoters.
Cumulative Capital Pvt. Ltd. operates as a joint book running lead manager.
Catalyst Capital Partners Pvt. Ltd. acts as the other lead manager for this offer.
The primary lead manager handled 7 public issues during the last 3 fiscal periods.
0 out of these 7 listings closed below the initial offer price on listing dates.
KFin Technologies Ltd. functions as the official registrar to this public issue.

Peer Comparison

Below is the comparison of the company with its listed peers using data from (May 29, 2026). (The corporate management selected Zydus Wellness and Nestle India as listed peers for comparison. Zydus Wellness trades at a high P/E ratio of 46.22 based on recent disclosures. Nestle India trades at a premium P/E ratio of 88.86 based on market pricing. These giant consumer brands do not offer a direct comparison due to massive differences in operational scale.)

Company Name	EPS (Basic)	NAV (₹ per share)	P/E (x)	RoNW (%)
Hexagon Nutrition Limited	₹1.75	₹15.91	25.71	12.46%
Zydus Wellness Limited	₹10.90	₹178.26	46.22	6.12%
Nestlé India Limited	₹16.63	₹21.35	88.86	77.91%

Financial data sourced from annual reports and stock exchange data, using restated financial statements for 2024-25. NAV per share (closing net worth divided by weighted average number of paid-up equity shares) and RoNW (net profit after tax divided by closing net worth).

IPO Review & Analyst Rating

The nutritional player controls a rising market share with an active distribution network spanning over 75 nations. The entire public issue contains an offer for sale component so the company gets zero expansion money.

Analyst Name	Recommendation
Overall Verdict	Subscribe for Long-Term – Neutral to Positive

Disclaimer: The information on the site is informational only. The contents of this blog are not financial advice. You should not invest in any stock market instrument without consulting your Financial advisor.

Sanjay Bambhaniya

Sanjay has 8+ years of experience in data-driven IPO insights. His expertise in digital marketing and web development complements his financial knowledge and helps him to develop effective fintech solutions. He is an entrepreneur and director who helps investors understand complex primary market trends in easy-to-understand IPO reports, news, and updates.

Discussion & Feedback

0 Comments

No comments yet. Be the first to share your thoughts!